Results 191 to 200 of about 11,287 (253)

A latent class analysis of clinical complexity: Secondary analysis of the collaboration leading to addiction treatment and recovery from other stresses (CLARO) randomized trial

Addiction, Volume 121, Issue 10, Page 2833-2844, October 2026.
Abstract Background and aims Individuals with opioid use disorder (OUD) frequently present with co‐occurring mental health conditions such as depression and posttraumatic stress disorder (PTSD), along with other mental health substance use disorders, physical health conditions and social determinants that together comprise ‘clinical complexity ...
Megan S. Schuler, Rebecca Weir, Colleen M. McCullough, Grace M. Hindmarch, Beth Ann Griffin, Kirsten Becker, Lisa S. Meredith, Katherine E. Watkins   +7 more
wiley   +1 more source

Prenatal opioid exposure, and health, social and educational outcomes for school‐aged children: A systematic review

Addiction, Volume 121, Issue 10, Page 2633-2645, October 2026.
Abstract Background and aims Recent decades have seen a rise in the number of pregnancies exposed to opioids. Whilst evidence of the impact of such exposure on pregnancy and infant outcomes is fairly robust, the impact of prenatal opioid exposure (POE) on longer‐term outcomes for children and young people remains unclear.
Louise Marryat, Dawood Gashgari, Shona Shinwell, Vicky Mitchell, Catriona Connell, Gale Macleod, Senga Robertson, Anne Whittaker, Alison McFadden   +8 more
wiley   +1 more source

Opioid Allergy Registrations in Danish Electronic Health Records: A Multihospital Register‐Based Study With Journal Audit

Basic &Clinical Pharmacology &Toxicology, Volume 139, Issue 4, October 2026.
ABSTRACT Accurate documentation of drug allergies is critical to prevent re‐exposure while avoiding unnecessary restrictions on safe pharmacotherapy. Although true opioid hypersensitivity is rare, adverse effects are frequently misclassified as allergies.
Andreas Halgreen Eiset, Signe Hertz Hansen, Sara Buttrup Rosenquist, Kenneth Skov, Lene Heise Garvey, Peter Gaarsdal Uhrbrand, Eva Aggerholm Sædder   +6 more
wiley   +1 more source

Sex Disparities in Hepatitis C Treatment Initiation: Role of Universal Access to DAA in France (ANRS FANTASIO 2)

Liver International, Volume 46, Issue 10, October 2026.
ABSTRACT Background and Aims Ensuring access to direct‐acting antivirals (DAA) for all individuals concerned is a priority in hepatitis C elimination efforts. We analysed sex disparities in DAA initiation in France over a 9‐year period spanning before and after August 2017, when the country implemented universal DAA access.
Fabienne Marcellin, Clémence Ramier, Cécile Brouard, Vincent Di Beo, Yoann Allier, Abbas Mourad, Morgane Bureau‐Stoltmann, Philippe Sogni, Sylvie Deuffic‐Burban, Patrizia Carrieri, Benjamin Rolland, Marc Bourliere, Camelia Protopopescu   +12 more
wiley   +1 more source

Establishment of a humanized patient‐derived xenograft mouse model of high‐grade serous ovarian cancer for preclinical evaluation of combination immunotherapy

Molecular Oncology, Volume 20, Issue 9, Page 2203-2219, September 2026.
We have established a humanized orthotopic patient‐derived xenograft (Hu‐oPDX) mouse model of high‐grade serous ovarian cancer (HGSOC) that recapitulates human tumor–immune interactions. Using combined anti‐PD‐L1/anti‐CD73 immunotherapy, we demonstrate the model's improved biological relevance and enhanced translational value for preclinical ...
Luka Tandaric, Line Bjørge, Martine Rott Lode, Cecilie Fredvik Torkildsen, Pia Aehnlich, Rammah Elnour, Daniela Elena Costea, Lars Andreas Akslen, Liv Cecilie Vestrheim Thomsen, Emmet McCormack, Katrin Kleinmanns   +10 more
wiley   +1 more source

Impact of Withdrawal of Extended‐Release Morphine 5 mg on Hospital Analgesic Utilization

Basic &Clinical Pharmacology &Toxicology, Volume 139, Issue 4, October 2026.
Mille Vraa Gamborg Eisenhardt, Maja Beck Mejlholm, Lisa Greve Routhe, Anne Estrup Olesen, Astrid Johannesson Hjelholt   +4 more
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Buprenorphine

BMJ Supportive & Palliative Care, 2022
.
Mellar P Davis, Bertrand Behm, Carlos Fernandez   +2 more
openaire   +3 more sources

The effects of buprenorphine in buprenorphine-maintained volunteers

Psychopharmacology, 1997
Buprenorphine is a mu opioid partial agonist currently used as an analgesic, and being developed for the treatment of opioid dependence. The purpose of this study was to determine the abuse liability of parenteral buprenorphine in volunteers maintained on daily sublingual (SL) buprenorphine (8 mg).
E C, Strain, S L, Walsh, K L, Preston, I A, Liebson, G E, Bigelow   +4 more
openaire   +2 more sources

Buprenorphine kinetics

Clinical Pharmacology and Therapeutics, 1980
Buprenorphine kinetics was determined in surgical patients using radioimmunoassay. Buprenorphine was measured in the plasma of 24 patients who had received 0.3 mg buprenorphine intraoperatively. After 3 hr 10 of these patients then received a further 0.3 mg buprenorphine intravenously for postoperative pain relief, and 11 patients were given 0.3 mg ...
R E, Bullingham, H J, McQuay, A, Moore, M R, Bennett   +3 more
openaire   +2 more sources

Buprenorphine

Drug and Alcohol Dependence, 1985
Buprenorphine is a mixed agonist-antagonist with high affinity at both mu and kappa opiate receptors. Its pharmacological profile is determined primarily by partial agonism at mu-receptors and unusually slow kinetics at these receptors. Its intrinsic activity is such that in nearly all clinical situations it is as effective an analgesic as morphine ...
openaire   +2 more sources